OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis $0.15 +0.00 (+0.85%) As of 10/2/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsOwnershipSEC FilingsShort Interest About Northwest Biotherapeutics Stock (OTCMKTS:NWBO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NWBO alerts:Sign Up Key Stats Today's Range$0.15▼$0.1650-Day Range$0.15▼$0.1952-Week Range$0.14▼$0.34Volume1.51 million shsAverage Volume2.41 million shsMarket Capitalization$266.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing personalized cancer immunotherapies. Its lead platform uses a patient’s own dendritic cells, which are immune cells collected from the patient and prepared to recognize and stimulate an immune response against tumor tissue. The company’s principal investigational product is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational treatment intended for injection directly into inoperable solid tumors. These products remain investigational and are not broadly approved cancer treatments. Northwest Biotherapeutics has conducted clinical development activities in the United States and Europe, including the United Kingdom and Germany. The company has worked with manufacturing and clinical partners in the United Kingdom, where its personalized vaccine manufacturing operations have been based. Linda Powers has served as the company’s chief executive officer and chairwoman.AI Generated. May Contain Errors. Read More Northwest Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreNWBO MarketRank™: Northwest Biotherapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Northwest Biotherapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Northwest Biotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.46% of the float of Northwest Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverNorthwest Biotherapeutics has a short interest ratio ("days to cover") of 19.76, which indicates bearish sentiment.Change versus previous monthShort interest in Northwest Biotherapeutics has recently increased by 7.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNorthwest Biotherapeutics does not currently pay a dividend.Dividend GrowthNorthwest Biotherapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Northwest Biotherapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for NWBO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.40% of the stock of Northwest Biotherapeutics is held by insiders.Percentage Held by Institutions0.04% of the stock of Northwest Biotherapeutics is held by institutions.Read more about Northwest Biotherapeutics' insider trading history. Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NWBO Stock News HeadlinesNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Breaks Below Two Hundred Day Moving Average - Time to Sell?October 3 at 2:41 AM | americanbankingnews.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below 200-Day Moving Average - Here's WhySeptember 25, 2026 | americanbankingnews.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 3 at 1:00 AM | Reagan Gold Group (Ad)Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance CompanyAugust 6, 2026 | prnewswire.comNORTHWEST BIOTHRPUTCS INC by Northwest Biotherapeutics, Inc. Insider Trading ActivityJuly 18, 2026 | benzinga.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax-L For Glioblastoma Using Individual Patient Level Data ...July 8, 2026 | finanznachrichten.deNorthwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent AnalysesJuly 8, 2026 | prnewswire.comNorthwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual MeetingJuly 2, 2026 | prnewswire.comSee More Headlines NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed this year? Northwest Biotherapeutics' stock was trading at $0.23 at the beginning of the year. Since then, NWBO stock has decreased by 33.2% and is now trading at $0.1537. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) announced its quarterly earnings data on Friday, August, 14th. The biotechnology company reported ($0.01) EPS for the quarter. The biotechnology company earned $0.81 million during the quarter. How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Intel (INTC), Advanced Micro Devices (AMD) and Meta Platforms (META). Company Calendar Last Earnings8/14/2026Today10/03/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees20Year Founded1998Profitability EPS (Trailing Twelve Months)($18.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.16 million Net Margins-1,736.35% Pretax Margin-1,761.07% Return on EquityN/A Return on Assets-56.34% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.04 Sales & Book Value Annual Sales$1.38 million Price / Sales193.30 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-3.84Miscellaneous Outstanding Shares1,735,560,000Free Float1,693,907,000Market Cap$266.76 million OptionableNot Optionable Beta-0.62 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:NWBO) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Northwest Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NWBO Stock Alerts